Rex Fang & Innovation Equity Premium Income ETF vs Tilray Brands Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Rex Fang & Innovation Equity Premium Income ETF is the larger of the two by market cap, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Tilray Brands Inc for 31 Days on average.
| FEPI | TLRY | |
|---|---|---|
Market Cap | $746.48M | $530.54M |
Volume | 334,337 | 9,099,075 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $21.00 |
52-Week Low | $37.98 | $3.57 |
Typical Hold Time | 56 Days | 31 Days |
Enterprise Value | — | $684.46M |
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.51, down 0.18% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on concentrated AI and mega-cap tech holdings, generating high weekly distributions averaging $0.20-0.21. Recent articles highlight its 25% trailing yield but note capped upside potential and underperformance versus peers in total return during tech rallies.
The outlook balances high income generation against significant risk from tech concentration and volatility dependence. While the covered call strategy funds substantial dividends, it limits capital appreciation during market upswings. Key risks include drawdown vulnerability if tech stocks decline and competitive pressure from higher-performing income alternatives. Analyst sentiment remains cautious due to the trade-off between yield and total return potential.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →